| Headline: | Radiance Biopharma to Present at LSX World Congress 2024 |
| Location: | US |
| Post Date: | Apr 26, 2024 12:18 PM |
| TAG ID: | awire157358 |
| DocID: | 856824 |
| Word Count: | approx. 307 words |
| Full story: | |
| Presentation on Monday, April 29 th at 11:15 AM (London Time) BOSTON MA / ACCESSWIRE / April 26, 2024 / Radiance Biopharma ("Radiance" or the "Company"), a biopharmaceutical company specializing in the development of novel Antibody Drug Conjugates (ADCs) and Bispecific ADCs (BsADCs) treatments for cancers, today announced that Robert Brooks, JD, Chief Executive Officer of Radiance will present at the LSX World Congress 2024 on Monday, April 29, 2024 at 11:15AM (GMT+1) in London, England. In addition to the presentation, Mr. Brooks will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, visit https://informaconnect.com/lsx-world-congress/ A replay of the presentation will be made available on the Company's website, www.Radiancebiopharma.com , following the conclusion of the conference. About LSX World Congress 2024 The 10th LSX World Congress is the leading partnering, strategy and investment event in Europe, with qualified 1:1 partnering at its core. The event brings together the CEOs and senior decision makers from the world's most innovative biopharma, medtech and healthtech companies with investors, senior BD&L teams, R&D leaders and industry KOLs. Together, they share best practice, forge partnerships and investments - all geared at putting capital and ideas to work to help create the world's future medicines and improve patient outcomes. About Radiance Biopharma, Inc. Radiance Biopharma Inc. is a biotechnology company focused on the discovery, development and commercialization of Antibody Drug Conjugates and next generation Bispecfic Antibody Drug Conjugates. Radiance's lead asset RB-201 is a 'First in Class' anti-HER2/TROP2 Bispecfic Antibody Drug Conjugate, that has demonstrated significant efficacy in animal studies in various solid tumors. Radiance is planning to conduct a Phase 1 Clinical Trial in early 2025. For more information, please visit www.Radiancebiopharma.com . Investor Relations Contact Radiance Biopharma [email protected] Tel: (617) 621-7143 SOURCE: Radiance Biopharma View the original press release on accesswire.com |
|
